8
Participants
Start Date
May 19, 2020
Primary Completion Date
April 16, 2021
Study Completion Date
April 16, 2021
ABBV-467
Intravenous (IV) Infusion
Alfred Health /ID# 214665, Melbourne
St Vincent's Hospital Melbourne /ID# 222066, Fitzroy
Royal Adelaide Hospital /ID# 223354, Adelaide
Royal Perth Hospital /ID# 225498, Perth
Perth Blood Institute Ltd /ID# 226650, Nedlands
National Taiwan University Hospital /ID# 209322, Taipei City
CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 214739, Madrid
Hospital Universitario Fundacion Jimenez Diaz /ID# 214672, Madrid
Hospital Universitario Virgen de la Victoria /ID# 214756, Málaga
CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 217170, Pamplona
China Medical University Hosp /ID# 209323, Taichung
CHU de Nantes, Hotel Dieu -HME /ID# 215480, Nantes
City of Hope /ID# 209786, Duarte
Hopital Henri Mondor /ID# 214588, Créteil
Sheba Medical Center /ID# 214065, Ramat Gan
University of Arizona Cancer Center - North Campus /ID# 219102, Tucson
Hackensack Univ Med Ctr /ID# 221035, Hackensack
Lifespan Cancer Institute at Rhode Island Hospital /ID# 215418, Providence
Prisma Health Cancer Institute-Faris Road /ID# 219076, Greenville
Nagoya City University Hospital /ID# 214696, Nagoya
National Cancer Center Hospital East /ID# 214697, Kashiwa-shi
Kyushu University Hospital /ID# 220800, Fukuoka
National Cancer Center Hospital /ID# 214801, Chuo-ku
Hospital Universitario Vall d'Hebron /ID# 214690, Barcelona
Lead Sponsor
AbbVie
INDUSTRY